Evidence map›Paper›PMID 24832667›Full record

ArticleBiology2013

Next-generation sequencing: from understanding biology to personalized medicine.

Karen S Frese, Hugo A Katus, Benjamin Meder

Abstract read
In one paragraph

Article in Biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Omics-Driven Biotechnology for Industrial Applications.Frontiers in bioengineering and biotechnology · 2021
    Review
  12. Review
  13. Microsatellite instability in colorectal cancer.Acta bio-medica : Atenei Parmensis · 2018
    Review
  14. The genetic basis of disease.Essays in biochemistry · 2018
    Review
  15. Clinical Interpretation of Genomic Variations.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2016
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Karen S FreseDepartment of Internal Medicine III, University of Heidelberg, Heidelberg 69120, Germany. karen.frese@med.uni-heidelberg.de.
Hugo A KatusDepartment of Internal Medicine III, University of Heidelberg, Heidelberg 69120, Germany. hugo.katus@med.uni-heidelberg.de.
Benjamin MederDepartment of Internal Medicine III, University of Heidelberg, Heidelberg 69120, Germany. benjamin.meder@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within just a few years, the new methods for high-throughput next-generation sequencing have generated completely novel insights into the heritability and pathophysiology of human disease. In this review, we wish to highlight the benefits of the current state-of-the-art sequencing technologies for genetic and epigenetic research. We illustrate how these technologies help to constantly improve our understanding of genetic mechanisms in biological systems and summarize the progress made so far. This can be exemplified by the case of heritable heart muscle diseases, so-called cardiomyopathies. Here, next-generation sequencing is able to identify novel disease genes, and first clinical applications demonstrate the successful translation of this technology into personalized patient care.

Identifiers

PMID24832667
PMCPMC4009863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.